Skip to main content
SpringerLink
Log in

FAK as a Target for Therapy in Head and Neck Cancer

  • Chapter
  • First Online:
Molecular Determinants of Head and Neck Cancer

Part of the book series: Current Cancer Research ((CUCR))

  • 553 Accesses

Abstract

Despite decades of concerted effort, treatments for head and neck squamous cell carcinoma (HNSCC) have remained largely unchanged, with tumors typically managed using a combination of surgery, radiotherapy, and cytotoxic chemotherapy. Suboptimal efficacy and often severe toxicities associated with some of these treatments have encouraged development of targeted therapies that may overcome these limitations. One promising avenue of therapeutic development in HNSCC in particular has addressed integrins and integrin-mediated signaling, which mediates interactions between the tumor and the extracellular matrix (ECM) and can potentially be targeted by inhibition of the integrin-associated focal adhesion kinase (FAK). This chapter summarizes FAK structure-function relationships and how FAK impacts multiple cellular processes relevant to HNSCC, including survival and invasion. We will discuss the development of targeted FAK inhibitors, and combinatorial strategies incorporating FAK inhibition, with comparisons between human papillomavirus (HPV)-positive and HPV-negative HNSCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic – a review of epidemiology, biology, virus detection and issues in management. Lancet Oncol. 2010;11(8):781–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Integrins. 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26867/.

  5. Kanner SB, Reynolds AB, Parsons JT. Immunoaffinity purification of tyrosine-phosphorylated cellular proteins. J Immunol Methods. 1989;120(1):115–24.

    Article  PubMed  CAS  Google Scholar 

  6. Mitra SK, Schlaepfer DD. Integrin-regulated FAK–Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18(5):516–23.

    Article  PubMed  CAS  Google Scholar 

  7. Yoon H, Dehart JP, Murphy JM, Lim S-TS. Understanding the roles of FAK in Cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015;63(2):114–28.

    Article  PubMed  CAS  Google Scholar 

  8. Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci. 2014;19:687–706.

    Article  CAS  Google Scholar 

  9. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem. 1997;272(24):15442–51.

    Article  PubMed  CAS  Google Scholar 

  10. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(4):1133–9.

    Article  CAS  Google Scholar 

  11. Saito Y, Mori S, Yokote K, Kanzaki T, Saito Y, Morisaki N. Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Biochem Biophys Res Commun. 1996;224(1):23–6.

    Article  PubMed  CAS  Google Scholar 

  12. Danilkovitch A, Leonard EJ. Kinases involved in MSP/RON signaling. J Leukoc Biol. 1999;65(3):345–8.

    Article  PubMed  CAS  Google Scholar 

  13. Aoto H, Sasaki H, Ishino M, Sasaki T. Nuclear translocation of cell adhesion kinase beta/proline-rich tyrosine kinase 2. Cell Struct Funct. 2002;27(1):47–61.

    Article  PubMed  CAS  Google Scholar 

  14. Lim S-T, Chen XL, Lim Y, Hanson DA, Vo T-T, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29(1):9–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, et al. Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell. 2015;163(1):160–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Polte TR, Hanks SK. Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci U S A. 1995;92(23):10678–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16(7):3327–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Hildebrand JD, Taylor JM, Parsons JT. An SH3 domain-containing GTPase-activating protein for rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol. 1996;16(6):3169–78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Wu X, Gan B, Yoo Y, Guan J-L. FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell. 2005;9(2):185–96.

    Article  PubMed  CAS  Google Scholar 

  20. Hildebrand JD, Schaller MD, Parsons JT. Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase. Mol Biol Cell. 1995;6(6):637–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein Talin. J Biol Chem. 1995;270(28):16995–9.

    Article  PubMed  CAS  Google Scholar 

  22. Longhurst CM, Jennings LK. Integrin-mediated signal transduction. Cell Mol Life Sci CMLS. 1998;54(6):514–26.

    Article  PubMed  CAS  Google Scholar 

  23. Wang P, Ballestrem C, Streuli CH. The C terminus of Talin links integrins to cell cycle progression. J Cell Biol. 2011;195(3):499–513.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Lawson C, Lim S-T, Uryu S, Chen XL, Calderwood DA, Schlaepfer DD. FAK promotes recruitment of Talin to nascent adhesions to control cell motility. J Cell Biol 2012;196(3):223–232.

    Google Scholar 

  25. Zhang X, Chattopadhyay A, Ji Q, Owen JD, Ruest PJ, Carpenter G, et al. Focal adhesion kinase promotes phospholipase C-γ1 activity. Proc Natl Acad Sci U S A. 1999;96(16):9021–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Chen H-C, Appeddu PA, Isoda H, Guan J-L. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem. 1996;271(42):26329–34.

    Article  PubMed  CAS  Google Scholar 

  27. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995;15(2):954–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Li L, Okura M, Imamoto A. Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. Mol Cell Biol. 2002;22(4):1203–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO. Src-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 2004;24(18):8113–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J. 2001;360(Pt 1):255–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-met receptor and Src kinases. Oncogene. 2006;25(16):2367–78.

    Article  PubMed  CAS  Google Scholar 

  32. Arold ST, Hoellerer MK, Noble MEM. The structural basis of localization and signaling by the focal adhesion targeting domain. Structure. 2002; 10(3):319–27. London, England: 1993.

    Google Scholar 

  33. Flinder LI, Timofeeva OA, Rosseland CM, Wierød L, Huitfeldt HS, Skarpen E. EGF-induced ERK-activation downstream of FAK requires rac1-NADPH oxidase. J Cell Physiol. 2011;226(9):2267–78.

    Article  PubMed  CAS  Google Scholar 

  34. Sieg DJ, Ilić D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK-cell migration. EMBO J. 1998;17(20):5933–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Yue Y, Li Z-N, Fang Q-G, Zhang X, Yang L-L, Sun C-F, et al. The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro. Oncol Rep. 2015;34(6):3280–7.

    Article  PubMed  CAS  Google Scholar 

  36. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta BBA – Mol Cell Biol Lipids. 2013;1833(12):3481–98.

    Article  CAS  Google Scholar 

  37. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619–26.

    Article  PubMed  CAS  Google Scholar 

  38. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK) induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of fak in a human leukemic cell line, HL-60. J Biol Chem. 2000;275(21):16309–15.

    Article  PubMed  CAS  Google Scholar 

  39. Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther. 2013;12(2):162–72. https://doi.org/10.1158/1535-7163. MCT-12-0701. Epub 2012 Dec 12. PubMed PMID: 23243059; PubMed Central PMCID: PMC3570595.

    Google Scholar 

  40. Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR, et al. p53 regulates FAK expression in human tumor cells. Mol Carcinog. 2008;47(5):373–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse C-K, Lark AA, Livasy CA, et al. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009;125(7):1735–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol. 1998;18(5):2571–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem. 2004;279(31):33024–34.

    Article  PubMed  CAS  Google Scholar 

  44. Kamarajan P, Bunek J, Lin Y, Nunez G, Kapila YL. Receptor-interacting protein shuttles between cell death and survival signaling pathways. Mol Biol Cell. 2010;21(3):481–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Tong L, Tergaonkar V. Rho protein GTPases and their interactions with NFκB: crossroads of inflammation and matrix biology. Biosci Rep. 2014;34(3):e00115. https://doi.org/10.1042/BSR20140021. Review. PubMed PMID: 24877606; PubMed Central PMCID: PMC4069681.

    Google Scholar 

  46. You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, et al. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Rep. 2015;10(12):2055–68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. O’Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007;67(19):8975–9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Nikonova AS, Gaponova AV, Kudinov AE, Golemis EA. CAS proteins in health and disease: an update. IUBMB Life. 2014;66(6):387–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. O’Neill GM, Fashena SJ, Golemis EA. Integrin signalling: a new cas(t) of characters enters the stage. Trends Cell Biol. 2000;10(3):111–9.

    Article  PubMed  Google Scholar 

  50. Lucas JT, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 2010;29(31):4449–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Schaller M. Paxillin: a focal adhesion-associated adaptor protein. Oncogene. 2001;20(44):6459–72.

    Article  PubMed  CAS  Google Scholar 

  52. Lim Y, Lim S-T, Tomar A, Gardel M, Bernard-Trifilo JA, Chen XL, et al. PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility. J Cell Biol. 2008;180(1):187–203.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 1999;112(Pt 16):2677–91.

    PubMed  CAS  Google Scholar 

  54. Tilghman R, Parsons JT. Focal adhesion kinase as a regulator of cell tension in the progression of cancer. Semin Cancer Biol. 2008;18(1):45–52.

    Article  PubMed  CAS  Google Scholar 

  55. Ammer A, Weed S. Cortactin branches out: roles in regulating protrusive actin dynamics. Cell Motil Cytoskelet. 2008;65(9):687–707.

    Article  CAS  Google Scholar 

  56. Segarra M, Vilardell C, Matsumoto K, Esparza J, Lozano E, Serra-Pages C, et al. Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19(13):1875–7.

    Google Scholar 

  57. Kwiatkowska A, Kijewska M, Lipko M, Hibner U, Kaminska B. Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta. 2011;1813(5):655–67.

    Article  PubMed  CAS  Google Scholar 

  58. Pan Y-R, Chen C-L, Chen H-C. FAK is required for the assembly of podosome rosettes. J Cell Biol. 2011;195(1):113–29.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Li X-Y, Zhou X, Rowe RG, Hu Y, Schlaepfer DD, Ilić D, et al. Snail1 controls epithelial–mesenchymal lineage commitment in focal adhesion kinase–null embryonic cells. J Cell Biol. 2011;195(5):729–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008;314(1):143–52.

    Article  PubMed  CAS  Google Scholar 

  61. Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, et al. TGFβ-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008;314(1):143–52.

    Article  PubMed  CAS  Google Scholar 

  62. Saito D, Kyakumoto S, Chosa N, Ibi M, Takahashi N, Okubo N, et al. Transforming growth factor-β1 induces epithelial–mesenchymal transition and integrin α3β1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug. J Biochem (Tokyo). 2013;153(3):303–15.

    Article  CAS  Google Scholar 

  63. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol. 2002;4(8):632–8.

    Article  PubMed  CAS  Google Scholar 

  64. Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, et al. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget. 2015;6(7):4757–72.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Rodrigo JP, Dominguez F, Suárez V, Canel M, Secades P, Chiara MD. Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007;133(2):145–50.

    Article  PubMed  Google Scholar 

  66. Fan H, Zhao X, Sun S, Luo M, Guan J-L. Function of focal adhesion kinase scaffolding to mediate Endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo. J Biol Chem. 2013;288(5):3322–33.

    Article  PubMed  CAS  Google Scholar 

  67. Te Boekhorst V, Preziosi L, Friedl P. Plasticity of cell migration in vivo and in silico. Annu Rev Cell Dev Biol. 2016;32:491–526.

    Article  CAS  Google Scholar 

  68. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008;135(3):510–23.

    Article  PubMed  CAS  Google Scholar 

  69. Ahn J, Sanz-Moreno V, Marshall CJ. The metastasis gene NEDD9 product acts through integrin β3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci. 2012;125(Pt 7):1814–26.

    Article  PubMed  CAS  Google Scholar 

  70. Ilić D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377(6549):539–44.

    Article  PubMed  Google Scholar 

  71. Shen T-L, Park AY-J, Alcaraz A, Peng X, Jang I, Koni P, et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 2005;169(6):941–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Zhao X, Peng X, Sun S, Park AYJ, Guan J-L. Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development. J Cell Biol. 2010;189(6):955–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med. 2010;2(12):516–28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006;25(44):5969–84.

    Article  PubMed  CAS  Google Scholar 

  75. Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, et al. FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun. 2013;4:2020: 1–11.

    Google Scholar 

  76. Weis SM, Lim S-T, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 2008;181(1):43–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009;69(2):466–74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Fan H, Guan J-L. Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J Biol Chem. 2011;286(21):18573–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Luo M, Zhao X, Chen S, Liu S, Wicha MS, Guan J-L. Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res. 2013;73(17):5591–602.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-β and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011;108(26):10544–9.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Kobayashi K, Takahashi H, Inoue A, Harada H, Toshimori S, Kobayashi Y, et al. Oct-3/4 promotes migration and invasion of glioblastoma cells. J Cell Biochem. 2012;113(2):508–17.

    Article  PubMed  CAS  Google Scholar 

  82. Lin Y-L, Han Z-B, Xiong F-Y, Tian L-Y, Wu X-J, Xue S-W, et al. Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol Cell Biochem. 2011;351(1–2):109–16.

    Article  PubMed  CAS  Google Scholar 

  83. Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM. Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. J Biol Chem. 2012;287(22):18656–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016;22(18):4643–50. https://doi.org/10.1158/1078-0432.CCR-15-2785. Epub 2016 Apr 1. PubMed PMID: 27036135; PubMed Central PMCID: PMC5061056.

    Google Scholar 

  86. Recher C, Ysebaert L, Beyne-Rauzy O, Mas VM-D, Ruidavets J-B, Cariven P, et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 2004;64(9):3191–7.

    Article  PubMed  CAS  Google Scholar 

  87. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut M-N, et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer. 2009;124(9):2124–34.

    Article  PubMed  CAS  Google Scholar 

  88. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, et al. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res. 2005;7:R194.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Canel M, Secades P, Rodrigo J-P, Cabanillas R, Herrero A, Suarez C, et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(11 Pt 1):3272–9.

    Article  CAS  Google Scholar 

  90. Omura G, Ando M, Saito Y, Kobayashi K, Yoshida M, Ebihara Y, et al. Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer. Head Neck. 2016;38(8):1164–9.

    Article  PubMed  Google Scholar 

  91. Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.

    Article  PubMed  CAS  Google Scholar 

  92. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis. 2008;29(6):1096–107.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Cance WG. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anti Cancer Agents Med Chem. 2013;13(4):546–54.

    Article  CAS  Google Scholar 

  94. Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res BCR. 2009;11(5):R68.

    Article  PubMed  CAS  Google Scholar 

  95. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013;105(19):1485–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Hallur G, Tamizharasan N, Sulochana SP, Saini NK, Zainuddin M, Mullangi R. LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2017;149:358–64.

    Article  PubMed  CAS  Google Scholar 

  97. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam J-O, Luo H, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther. 2010;9(10):778–90.

    Article  PubMed  CAS  Google Scholar 

  98. Zhang J, He D-H, Zajac-Kaye M, Hochwald SN. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle Georget Tex. 2014;13(19):3143–9.

    Article  CAS  Google Scholar 

  99. Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(12):2268–74.

    Article  CAS  Google Scholar 

  100. O’Brien S, Golubovskaya VM, Conroy J, Liu S, Wang D, Liu B, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget. 2014;5(17):7945–59.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA, Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem. 2009;52(15):4716–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, et al. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle Georget Tex. 2014;13(16):2542–53.

    Article  CAS  Google Scholar 

  103. Moen I, Gebre M, Alonso-Camino V, Chen D, Epstein D, McDonald DM. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis. 2015;32(8):799–817.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Ucar DA, Cox A, He D-H, Ostrov DA, Kurenova E, Hochwald SN. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Anti Cancer Agents Med Chem. 2011;11(7):629–37.

    Article  CAS  Google Scholar 

  105. Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, et al. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle Georget Tex. 2012;11(17):3250–9.

    Article  CAS  Google Scholar 

  106. Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, et al. A small-molecule inhibitor, 5′-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo. Anti Cancer Agents Med Chem. 2013;13(4):532–45.

    Article  CAS  Google Scholar 

  107. Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, et al. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer. 2013;13(1):342.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance [internet]. Chemotherapy Research and Practice. 2012. Available from: https://www.hindawi.com/journals/cherp/2012/283181/.

  109. Dragoj M, Milosevic Z, Bankovic J, Tanic N, Pesic M, Stankovic T. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma. Cell Oncol Dordr. 2017;40(1):47–62.

    Article  PubMed  CAS  Google Scholar 

  110. Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, et al. Inhibition of FAK kinase activity preferentially targets cancer stem cells. Oncotarget. 2017;8(31):51733–47.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007;67(22):10976–83.

    Article  PubMed  CAS  Google Scholar 

  112. Heffler M, Golubovskaya VM, Dunn KMB, Cance W. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Ther. 2013;14(8):761–72.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle. 2009;8(15):2435–43.

    Article  PubMed  CAS  Google Scholar 

  114. Kurio N, Shimo T, Fukazawa T, Okui T, Hassan NMM, Honami T, et al. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. Oral Oncol. 2012;48(11):1159–70.

    Article  PubMed  CAS  Google Scholar 

  115. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30(13):1527–33.

    Google Scholar 

  116. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi H-J, Hansen JM, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016;126(5):1885–96.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Sandfort V, Koch U, Cordes DN. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol. 2007;83(11–12):727–32.

    Article  PubMed  CAS  Google Scholar 

  118. Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M, et al. β1Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest. 2012;122(4):1529–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Eke I, Dickreuter E, Cordes N. Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition. Radiother Oncol. 2012;104(2):235–42.

    Google Scholar 

  120. Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene. 2016;35(11):1353–62.

    Article  PubMed  CAS  Google Scholar 

  121. Albert M, Schmidt M, Cordes N, Dörr W. Modulation of radiation-induced oral mucositis (mouse) by selective inhibition of β1 integrin. Radiother Oncol. 2012;104(2):230–4.

    Google Scholar 

  122. Ning S, Tian J, Marshall DJ, Knox SJ. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010;70(19):7591–9.

    Article  PubMed  CAS  Google Scholar 

  123. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther. 2008;7(6):1569–78.

    Article  PubMed  CAS  Google Scholar 

  124. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2008;25(2):139–48.

    Article  PubMed  CAS  Google Scholar 

  125. Steglich A, Vehlow A, Eke I, Cordes N. α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells. Cancer Lett. 2015;357(2):542–8.

    Article  PubMed  CAS  Google Scholar 

  126. Hehlgans S, Eke I, Cordes N. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Int J Radiat Oncol Biol Phys. 2012;83(5):e669–76.

    Article  PubMed  CAS  Google Scholar 

  127. Hehlgans S, Lange I, Eke I, Cordes N. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol. 2009;92(3):371–8.

    Google Scholar 

  128. Tang K-J, Constanzo JD, Venkateswaran N, Melegari M, Ilcheva M, Morales JC, et al. Focal adhesion kinase regulates the DNA damage response and its inhibition Radiosensitizes mutant KRAS lung Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(23):5851–63.

    Article  CAS  Google Scholar 

  129. Graham K, Moran-Jones K, Sansom OJ, Brunton VG, Frame MC. FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells. PLoS One. 2011;6(12):e27806.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–9.

    Article  PubMed  Google Scholar 

  131. Dok R, Glorieux M, Holacka K, Bamps M, Nuyts S. Dual role for p16 in the metastasis process of HPV positive head and neck cancers. Mol Cancer. 2017;16:113.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Fåhraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J. 1999;18(8):2106–18.

    Article  PubMed  PubMed Central  Google Scholar 

  133. McCormack SJ, Brazinski SE, Moore JL, Werness BA, Goldstein DJ. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene. 1997;15(3):265–74.

    Article  PubMed  CAS  Google Scholar 

  134. Byers LA, Diao L, Ng PKS, Heymach C, Fan YH, El-Naggar AK, et al. Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy. J Clin Oncol. 2014;32(15_suppl):6030.

    Google Scholar 

  135. Du M, Fan X, Hong E, Chen JJ. Interaction of oncogenic papillomavirus E6 proteins with fibulin-1. Biochem Biophys Res Commun. 2002;296(4):962–9.

    Article  PubMed  CAS  Google Scholar 

  136. Vande Pol SB, Brown MC, Turner CE. Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif. Oncogene. 1998;16(1):43–52.

    Article  PubMed  CAS  Google Scholar 

  137. DeMasi J, Chao MC, Kumar AS, Howley PM. Bovine papillomavirus E7 Oncoprotein inhibits Anoikis. J Virol. 2007;81(17):9419–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  138. Huh K-W, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Münger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A. 2005;102(32):11492–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.

    Article  CAS  Google Scholar 

  140. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck Cancer. Cancer Res. 2013;73(15):4791–800.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic, Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nassim Khosravi & John Heymach

  2. Department of Clinical Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Heath Skinner

Authors
  1. Nassim Khosravi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heath Skinner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Heymach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Heymach .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

    Barbara Burtness

  2. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Erica A. Golemis

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khosravi, N., Skinner, H., Heymach, J. (2018). FAK as a Target for Therapy in Head and Neck Cancer. In: Burtness, B., Golemis, E. (eds) Molecular Determinants of Head and Neck Cancer. Current Cancer Research. Humana Press, Cham. https://doi.org/10.1007/978-3-319-78762-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78762-6_17

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-78761-9

  • Online ISBN: 978-3-319-78762-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation